Richmond, CA, United States of America

Victoria A Crebbin

This inventor holds 2 USPTO granted patents. Top assignees: Chiron Diagnostics Corporation, Ciba Corning Diagnostics Corp.. Active years: 1994-1997.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 37(Granted Patents)


Location History:

  • Richmond, CA (US) (1994)
  • Alameda, CA (US) (1997)

Company Filing History:


Years Active: 1994-1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Victoria A Crebbin: Innovator in Cancer Detection

Introduction

Victoria A Crebbin is a notable inventor based in Richmond, CA (US). She has made significant contributions to the field of cancer diagnostics, holding 2 patents that focus on innovative methods for detecting malignant tumors.

Latest Patents

Her latest patents include the "Epidermal Growth Factor Receptor Ectodomain" and "Method of Cancer Detection." These patents provide diagnostic and prognostic methods for detecting elevated levels of a portion of the epidermal growth factor receptor (EGFr) in body fluids, particularly serum. The methods are designed for mammals carrying a malignant tumor burden. The patents disclose substantially pure compositions comprising EGFr ectodomain protein and/or fragments, along with test kits for performing the assays.

Career Highlights

Victoria has worked with prominent companies in the diagnostics field, including Ciba Corning Diagnostics Corporation and Chiron Diagnostics Corporation. Her experience in these organizations has contributed to her expertise in developing diagnostic methods for cancer detection.

Collaborations

Some of her notable coworkers include Jeanne P Harvey and Roger P Walker, who have collaborated with her on various projects throughout her career.

Conclusion

Victoria A Crebbin's work in cancer detection has paved the way for advancements in diagnostic methods, showcasing her innovative spirit and dedication to improving healthcare. Her contributions continue to impact the field significantly.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…